<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041000</url>
  </required_header>
  <id_info>
    <org_study_id>ADI-US-COPD-001</org_study_id>
    <nct_id>NCT02041000</nct_id>
  </id_info>
  <brief_title>Adipose Derived Cells for Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioheart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioheart, Inc.</source>
  <brief_summary>
    <textblock>
      The intent of this clinical study is to answer the questions: 1) Is the proposed treatment
      safe and 2) Is treatment effective in improving the disease pathology of patients with
      diagnosed with chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <description>Safety will be assessed as the occurrence/frequency (if applicable) of adverse events during the study procedures and for up to 6 months afterward.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>St. George Respiratory</measure>
    <time_frame>6 months</time_frame>
    <description>The St. George Respiratory questionnaire is an index developed to identify the quality of life of patients by measuring and quantifying health-related health status of patients with airflow obstruction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gold Classification</measure>
    <time_frame>6 months</time_frame>
    <description>The GOLD COPD staging system classifies people with COPD based on their degree of airflow limitation (obstruction). The airflow limitation is measured during pulmonary function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>6 months</time_frame>
    <description>Exercise capacity as measured as the distance a patient can walk over a 6 minute time period.</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adipose Derived Stem Cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A prior diagnosis of moderate or severe COPD

          -  GOLD III and IV

          -  Age between 18 and 85 years

        Exclusion Criteria:

          -  Females who are pregnant or nursing or females of childbearing potential who are
             unwilling to maintain contraceptive therapy for the duration of the study

          -  Life expectancy &lt; 6 months due to concomitant illnesses.

          -  Exposure to any investigational drug or procedure within 1 month prior to study entry
             or enrolled in a concurrent study that may confound results of this study.

          -  Active infectious disease patients known to have tested positive for HIV, HTLV, HBV,
             HCV, CMV (IgM &gt; IgG) and/or syphilis. will have an expert consulted as to patient
             eligibility based on the patient's infectious status

          -  Any illness which, in the Investigator's judgment, will interfere with the patient's
             ability to comply with the protocol, compromise patient safety, or interfere with the
             interpretation of the study results

          -  Patients on chronic immunosuppressive transplant therapy

          -  Known drug or alcohol dependence or any other factors which will interfere with the
             study conduct or interpretation of the results or who in the opinion of the
             investigator are not suitable to participate.

          -  Severe asthma that would contraindicate surgery

          -  History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in
             the last five years.

          -  Patients with Alpha-1

          -  Unwilling and/or not able to give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Comella</last_name>
    <role>Study Director</role>
    <affiliation>Bioheart, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Stem Cell Clinic</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>pulmonary</keyword>
  <keyword>stem cells</keyword>
  <keyword>emphysema</keyword>
  <keyword>lungs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

